Drug
Paclitaxel
Paclitaxel: highest development phase Phase 2, developed by Boehringer Ingelheim, Bristol-Myers Squibb, Jazz Pharmaceuticals and others. 6 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Boehringer Ingelheim, Bristol-Myers Squibb, Jazz Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Paclitaxel NCT01121406 | Phase 2 | Ovarian Neoplasms |
| Paclitaxel, vinorelbine, cisplatin NCT00198432 | Phase 2 | NSCLC Stage IIIB |
| Paclitaxel NCT01770301 | Phase 2 | Ovarian Sex-cord Stromal Tumor |
| Paclitaxel NCT00850577 | Phase 2 | Non-small Cell Lung Cancer (NSCLC) |
| Paclitaxel NCT06043427 | Phase 2 | Gastroesophageal Adenocarcinoma |
| Paclitaxel NCT04425018 | Phase 2 | Breast Cancer |
Latest
No recent events.
Follow Paclitaxel on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.